Paid Clinical Trials in Detroit, MI
As of June 2026, 810 paid clinical trials are recruiting in Detroit, Michigan. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Detroit offers studies at sites including Henry Ford Hospital for conditions such as Advanced Solid Tumor, Breast Cancer, Endometrial Cancer, Acute Myeloid Leukemia. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Detroit
Filter results
42 clinical trials
·Clear filters·↓ Download CSVAn Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
About research studies in Detroit
Detroit has approximately 810 recruiting research studies across a wide range of therapeutic areas. Michigan hosts University of Michigan Health, Henry Ford Health, and Corewell Health, running trials across oncology, neurology, and cardiology with a strong focus on precision medicine.
Top Research Study Locations in Detroit
Researchers run research studies in Detroit, MI at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Henry Ford Hospital | Acute Myeloid Leukemia, Melanoma, Anatomic Stage II Breast Cancer AJCC v8 | 151 |
| Karmanos Cancer Institute | Advanced Solid Tumor, Endometrial Cancer, Ovarian Cancer | 89 |
| Henry Ford Health System | Advanced Solid Tumor, Brain Tumor, Breast Cancer | 86 |
| Henry Ford Health | Heart Failure, Advanced Solid Tumor, Amyotrophic Lateral Sclerosis | 54 |
| Wayne State University/Karmanos Cancer Institute | Malignant Solid Neoplasm, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8 | 45 |
| Children's Hospital of Michigan | Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, Down Syndrome | 45 |
| Henry Ford Health Saint John Hospital | Anatomic Stage II Breast Cancer AJCC v8, Malignant Solid Neoplasm, Stage IIIB Lung Cancer AJCC v8 | 43 |
| Wayne State University | Infant, Low Birth Weight, Infant, Newborn, Infant, Premature | 26 |
| Barbara Ann Karmanos Cancer Institute | Breast Cancer, Non-small Cell Lung Cancer, Breast Neoplasms | 23 |
| Henry Ford Cancer Institute | Metastatic Solid Tumor, Acute Leukemia, Acute Myeloid Leukemia | 13 |
| John D. Dingell VA Medical Center, Detroit, MI | Obstructive Sleep Apnea, Sleep Apnea, Sleep Disordered Breathing | 11 |
| GSK Investigational Site | Neoplasms, Colonic Neoplasms, Hepatitis B | 9 |
| Henry Ford | ADHF, Atrial Fibrillation (AF), Brain Tumor - Metastatic | 7 |
| Henry Ford Health Hospital | ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome | 6 |
| Karmanos Cancer Center | Breast Neoplasms, Endometrial Cancer, Limited-stage Small Cell Lung Cancer (LS-SCLC) | 6 |
| Tolan Park Medical Building | PTSD, Polysubstance Abuse, Adolescence | 6 |
| Henry Ford St. John Hospital | Atrial Fibrillation, Cardiovascular Diseases, Coronary Artery Disease (CAD) | 5 |
| Ascension Saint John Hospital | Anatomic Stage IV Breast Cancer AJCC v8, Cardiotoxicity, Elevated CA15-3 or CEA or CA27-29 | 4 |
| Ascension St. John Hospital | High-Risk Percutaneous Coronary Intervention, Pulmonary Embolism, Rectal Cancer | 4 |
| Clinical Trial Site | Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency, Advanced Breast Cancer | 4 |
| Detroit Medical Center | Diabetes (DM), Diabetic Ketoacidosis, Gastric Emptying | 4 |
| Detroit Receiving Hospital | Traumatic Brain Injury, Lumbar Spinal Stenosis, Status Epilepticus | 4 |
| Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) | Advanced Melanoma, KRAS G12C-mutated Solid Tumors, Lung Cancer, KRAS, NRAS, HRAS-mutated NSCLC | 4 |
| Henry Ford Cancer Center | Locally Advanced Solid Tumor, Hemoglobinopathy, Metastatic Solid Tumor | 4 |
| Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center | Advanced Solid Tumor, Cutaneous Melanoma, Endometrial Carcinoma (EC) | 3 |
Active & Upcoming Studies in Detroit (2026)
Recruiting trials in Detroit grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (367 active studies)
- A Study of the TheraBionic P1 Device in Breast Cancer · Barbara Ann Karmanos Cancer Institute
- Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer · Phase 1, Phase 2 · University of Michigan Rogel Cancer Center
Cardiovascular (48 active studies)
- Light Utilization COX-Inhibitory Device Therapy for Infant Cardiac Arrest (LUTICA Study). The LUCID Device is Used in the Treatment of Ischemic Brain Reperfusion Injury Caused by Cardiac Arrest in Pediatric Patients. · Mitovation, Inc
- A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation · Phase 2 · Bayer
Neurology & pain (32 active studies)
- Behavioral Optimization to Overcome Obstructive Sleep Apnea Treatment Barriers · VA Office of Research and Development
- Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment · Phase 4 · VA Office of Research and Development
Mental health & behavior (11 active studies)
- Peer-Delivered Behavioral Activation in a CCBHC · Wayne State University
- Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery · Phase 1 · Wayne State University
Diabetes & metabolic (10 active studies)
- Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System · Insulet Corporation
- Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes · Insulet Corporation
Pediatric (6 active studies)
- Optimizing Pain Treatment in Children On Mechanical Ventilation · Phase 3 · Weill Medical College of Cornell University
- A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). · Phase 2, Phase 3 · Cytokinetics
HIV / STI (5 active studies)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) · Phase 2, Phase 3 · Merck Sharp & Dohme LLC
- Couples Motivational Interviewing to Reduce Drug Use and HIV Risk in Vulnerable Male Couples · Hunter College of City University of New York
Eye & vision (4 active studies)
- Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries · Henry Ford Health System
- Community Based Treatment for (ComBaT) Glaucoma · University of Michigan
Vaccines (3 active studies)
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised · Phase 3 · Pfizer
- Predictors of Post-COVID-19 Clinical and Cognitive Consequences · VA Office of Research and Development
Common conditions studied in Detroit
- Advanced Solid Tumor (19 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Breast Cancer (18 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Endometrial Cancer (18 active studies). Recruiting Endometrial Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Acute Myeloid Leukemia (14 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Multiple Myeloma (14 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Ovarian Cancer (14 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
Leading research sponsors in Detroit
- Henry Ford Health System
- National Cancer Institute (NCI)
- AstraZeneca
- NRG Oncology
- Wayne State University
Local regulations and guidelines
Clinical trials in Michigan are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Michigan research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Detroit. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Detroit
Hipa.ai aggregates every recruiting study in Detroit from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Detroit?
There are approximately 810 recruiting clinical trials in Detroit, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Detroit pay participants?
Most recruiting trials in Detroit compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Detroit?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Detroit?
The most common conditions under active study in Detroit include Advanced Solid Tumor (19), Breast Cancer (18), Endometrial Cancer (18), Acute Myeloid Leukemia (14), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Detroit?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Detroit on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Detroit?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Detroit?
Recruiting research sites in Detroit include Henry Ford Hospital, Karmanos Cancer Institute, Henry Ford Health System, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Detroit right now?
The largest active categories in Detroit are Cancer & tumors (367), Cardiovascular (48), Neurology & pain (32). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.